Cardiovascular drug reviews最新文献

Abbott-57219[SCH-40054]: A Novel Nasal Decongestant abbot -57219[SCH-40054]:一种新型减充血剂

Cardiovascular drug reviews Pub Date : 2007-04-02 DOI: 10.1111/J.1527-3466.1987.TB00512.X

J. Kyncl, S. Buckner, J. Debernardis, M. Winn, H. Brondyk, R. Dudley

引用次数: 0

DPI 201-106 DPI 201 - 106

Cardiovascular drug reviews Pub Date : 2007-04-02 DOI: 10.1111/J.1527-3466.1987.TB00508.X

Günter Scholtysik, Peter Rüegg

引用次数: 0

Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition? 血管紧张素受体阻滞剂和肾脏:可能优于ACE抑制?

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00184.X

M. Cooper, R. Webb, M. de Gasparo

引用次数: 11

Cardiovascular effects of raloxifene hydrochloride. 盐酸雷洛昔芬对心血管的影响。

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00183.X

A. Saitta, Nunziate Morabito, Nicola Frisina, Domenico Cucinotte, Francesco Corrado, R. D’Anna, D. Altavilla, G. Squadrito, L. Minutoli, Vincenzo Arcoraci, Francesco Cancellieri, F. Squadrito

{"title":"Cardiovascular effects of raloxifene hydrochloride.","authors":"A. Saitta, Nunziate Morabito, Nicola Frisina, Domenico Cucinotte, Francesco Corrado, R. D’Anna, D. Altavilla, G. Squadrito, L. Minutoli, Vincenzo Arcoraci, Francesco Cancellieri, F. Squadrito","doi":"10.1111/J.1527-3466.2001.TB00183.X","DOIUrl":"https://doi.org/10.1111/J.1527-3466.2001.TB00183.X","url":null,"abstract":"Raloxifene hydrochloride binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators (SERMs). Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different receptor subtypes in various tissues, and intracellular events after ligand binding. Raloxifene has estrogen-agonist effects on bone and lipids and estrogen antagonist effects on the breast and uterus. In addition to its well established effects on osteoporosis, recent preclinical and clinical findings suggest that raloxifene also possesses beneficial effects on the cardiovascular system. These findings indicated that raloxifene may have cardioprotective properties without an increased risk of cancer or other side effects. Raloxifene has been shown to reduce total and low-density lipoprotein cholesterol concentrations in plasma, an effect similar to that produced by estrogens. Unlike estrogens, however, raloxifene does not increase high-density lipoprotein cholesterol and triglyceride levels in plasma. Endothelium is thought to play an important role in the genesis of atherosclerosis. Several lines of evidence suggest that an intervention with endothelial function might influence the progression of coronary disease and the incidence of cardiovascular events. Raloxifene increases the nitric oxide/endothelin-1 ratio, and improves endothelium-dependent vasomotion in post-menopausal women to the same extent as estrogens. Furthermore, in two randomized trials on post-menopausal women raloxifene reduced homocysteine levels, another independent risk factor for the development of cardiovascular disease. Although estrogens remain the drugs of choice in the hormonal therapy of most postmenopausal women, raloxifene may represent and alternative in women who are at risk of coronary artery disease.","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82019977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 46

Bopindolol: Pharmacological Basis and Clinical Implications bopinddolol:药理基础和临床意义

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00180.X

T. Nagatomo, Y. Hosohata, T. Ohnuki, Takashi Nakamura, K. Hattori, J. Suzuki, M. Ishiguro

引用次数: 5

Basic experimental studies and clinical aspects of gadolinium salts and chelates. 钆盐及螯合物的基础实验研究及临床应用。

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00182.X

L. C. Adding, G. Bannenberg, L. Gustafsson

引用次数: 117

Pranidipine, a 1,4-dihydropyridine calcium channel blocker that enhances nitric oxide-induced vascular relaxation. Pranidipine，一种1,4-二氢吡啶钙通道阻滞剂，可增强一氧化氮诱导的血管舒张。

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00179.X

Toyoki Mori, H. Takase, K. Toide, T. Hirano, Toshimi Kambe, N. Nakayama, Arnold Schwartz

引用次数: 8

UR-3216: a manageable oral GPIIb/IIIa antagonist. UR-3216:口服GPIIb/IIIa拮抗剂。

Cardiovascular drug reviews Pub Date : 2006-06-09 DOI: 10.1111/J.1527-3466.2001.TB00181.X

K. Baba, Y. Aga, T. Nakanishi, T. Motoyama, H. Ueno

{"title":"UR-3216: a manageable oral GPIIb/IIIa antagonist.","authors":"K. Baba, Y. Aga, T. Nakanishi, T. Motoyama, H. Ueno","doi":"10.1111/J.1527-3466.2001.TB00181.X","DOIUrl":"https://doi.org/10.1111/J.1527-3466.2001.TB00181.X","url":null,"abstract":"UR-3216, a prodrug, is a novel, selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. The most important property of UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of UR-3216, binds to platelets for a long period of time, while the unbound drug is rapidly cleared. Therefore, after an initial loading dose of 0.1 mg/kg, only once daily repeated low maintenance doses of UR-3216 (< 0.05 mg/kg p.o.) are required. This regimen maintains a high level of inhibition of platelet aggregation and, due to a small peak-to-trough ratio, severe bleeding is avoided. The therapy with UR-3216 is easy to manage, because it has low peak-to-trough ratio and high efficacy (> 80% inhibition of platelet aggregation). In addition, UR-3216 does not produce excessive bleeding or thrombocytopenia and does not interact with abciximab. UR-3216 is excreted mostly in bile, so that it will not accumulate in patients with chronic renal dysfunction. UR-2316 has the following abciximab-like features: (a) its half-lives for residence on platelets, inhibition of platelets aggregation and bleeding time prolongation are 60 to 80 h, 24, and 2 h, respectively; (b) its receptor binding occupancy is similar to that of abciximab (Mab1 is inhibited and Mab2 is unaltered). In conclusion, UR-3216 is a promising, orally active GPIIb/IIIa antagonist for the treatment of cardiovascular diseases.","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88623938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Cardiovascular actions of berberine. 小檗碱的心血管作用。

Cardiovascular drug reviews Pub Date : 2006-06-07 DOI: 10.1111/J.1527-3466.2001.TB00068.X

C. Lau, X. Yao, Z. Chen, W. Ko, Yu Huang

引用次数: 259

Pharmacology of SCH00013: a novel Ca2+ sensitizer. SCH00013的药理学:一种新的Ca2+敏化剂。

Cardiovascular drug reviews Pub Date : 2006-06-07 DOI: 10.1111/J.1527-3466.2001.TB00075.X

M. Endoh, H. Sugawara, M. Mineshima

{"title":"Pharmacology of SCH00013: a novel Ca2+ sensitizer.","authors":"M. Endoh, H. Sugawara, M. Mineshima","doi":"10.1111/J.1527-3466.2001.TB00075.X","DOIUrl":"https://doi.org/10.1111/J.1527-3466.2001.TB00075.X","url":null,"abstract":"Cardiotonic agents that facilitate cardiac pump function by direct improvement of contractile dysfunction are indispensable for the treatment of hemodynamic disorders in acute myocardial failure and the aggravating phase of congestive heart failure. Cardiotonic agents currently available for the treatment of hemodynamic crisis in congestive heart failure are catecholamines, selective phosphodiesterase (PDE) III inhibitors and digitalis, all of which are Ca2+ mobilizers. Considering the number of serious adverse effects of these clinically available cardiotonic agents, development of agents that act via a novel mechanism of action may contribute to the progress of pharmacotherapy of congestive heart failure. Ca2+ sensitizers that act by increasing in myofilament Ca2+ sensitivity may be able to overcome the disadvantage of Ca2+ mobilizers. Ca2+ sensitizers do not increase activation energy, do not produce Ca2+ overload and may be effective even under pathophysiological states such as acidosis, myocardial stunning and heart failure. SCH00013 ((4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]-1,2,5,6-tetrahydropyrido-4-yl]pyridazin-3(2H)-one)) is a novel Ca2+ sensitizer that elicits a moderate positive inotropic effect without significant alteration of Ca2+ transients. SCH00013 does not have a positive chronotropic effect and has a weak PDE III inhibitory action and class III antiarrhythmic action. SCH00013 prolonged the survival in a animal heart failure model with genetic cardiomyopathy. The oral bioavailability of SCH00013 is high and equivalent to that via intravenous administration. The unique pharmacological profiles of SCH00013 imply that this agent may be potentially beneficial for pharmacotherapy of contractile dysfunction in congestive heart failure.","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89626178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8